In this article
Not all wavelengths of red and near-infrared light are equal. The difference between 630nm and 660nm — just 30 nanometres — can determine whether a therapy session targets superficial skin or reaches deep into muscle tissue. This reference page covers every major wavelength used in photobiomodulation, what the evidence says about each, and how to choose the right wavelengths for your goals.
Master Wavelength Reference Table
The following table summarises every therapeutically relevant wavelength from 620nm through 1100nm. Evidence strength ratings reflect the volume and quality of published clinical research as of early 2026.
| Wavelength | Type | Penetration Depth | Primary Applications | Evidence Strength | Key Study |
|---|---|---|---|---|---|
| 620nm | Visible red | 1-2mm (epidermis) | Superficial wound healing, mild acne | Moderate | Avci et al., 2013 (PMID: 23508258) |
| 630nm | Visible red | 1-3mm (epidermis/upper dermis) | Skin rejuvenation, collagen synthesis, wound healing | Strong | Wunsch & Matuschka, 2014 (PMID: 24286286) |
| 633nm | Visible red | 1-3mm (upper dermis) | Acne (often combined with blue light), dermatitis | Strong | Lee et al., 2007 (PMID: 17566756) |
| 640nm | Visible red | 2-3mm (dermis) | Photodynamic therapy adjunct, skin healing | Moderate | Morton et al., 2013 (PMID: 23621831) |
| 650nm | Visible red | 2-4mm (dermis) | Hair growth, skin texture, fibroblast stimulation | Moderate | Kim et al., 2013 (PMID: 23970445) |
| 660nm | Visible red | 3-5mm (deep dermis) | Skin rejuvenation, wound healing, inflammation, hair growth | Very strong | Hamblin, 2017 (PMID: 28748217) |
| 670nm | Visible red | 3-5mm (deep dermis) | Wound healing (NASA research), retinal health, mitochondrial function | Strong | Whelan et al., 2001 (PMID: 11706695) |
| 680nm | Visible red / edge NIR | 3-5mm (deep dermis) | Cellular energy, wound repair | Limited | — |
| 700nm | NIR (edge) | 3-5mm | Minimal research; transitional zone | Very limited | — |
| 720nm | NIR | 3-5mm | ”Dead zone” — poor absorption | Very limited | — |
| 740nm | NIR | 4-6mm | ”Dead zone” — limited therapeutic evidence | Very limited | — |
| 760nm | NIR | 5-8mm | ”Dead zone” — limited therapeutic evidence | Very limited | — |
| 780nm | NIR | 5-10mm (subcutaneous tissue) | Emerging research in nerve repair | Limited | Andreo et al., 2017 (PMID: 28508759) |
| 810nm | NIR | 10-20mm (muscle, bone) | Brain/cognitive function, TBI, deep tissue repair, pain relief | Very strong | Naeser et al., 2014 (PMID: 25587907) |
| 830nm | NIR | 15-25mm (deep muscle, bone) | Deep pain, joint conditions, inflammation, bone repair | Very strong | Bjordal et al., 2003 (PMID: 12580887) |
| 850nm | NIR | 20-30mm (deep tissue, joints) | Muscle recovery, deep pain, joint inflammation, bone density | Very strong | Ferraresi et al., 2012 (PMID: 22988275) |
| 880nm | NIR | 20-30mm (deep tissue) | Wound healing (NASA research), deep tissue penetration | Strong | Whelan et al., 2001 (PMID: 11706695) |
| 904nm | NIR (pulsed) | 30-40mm (bone, deep joints) | Pain management, arthritis, deep joint conditions | Strong | Bjordal et al., 2003 (PMID: 12580887) |
| 940nm | NIR | 25-35mm (deep tissue) | Deep tissue penetration, fat metabolism, emerging research | Moderate | Avci et al., 2009 (PMID: 20662037) |
| 980nm | NIR | 20-30mm | Water absorption peak — thermal effects dominate; used in some laser therapies | Moderate | — |
| 1060nm | NIR | 20-35mm (deep fat, bone) | Fat reduction, deep tissue, bone metabolism | Limited–Moderate | McRae & Boris, 2013 (PMID: 23508042) |
| 1072nm | NIR | 20-35mm | Bone healing, emerging research | Limited | — |
| 1100nm | NIR | 15-25mm (decreasing) | Edge of therapeutic window; water absorption increasing | Very limited | — |
The Visible Red Window: 620-700nm
The visible red spectrum is what most people picture when they think of red light therapy — the deep, warm glow that is visible to the naked eye. These wavelengths interact primarily with the skin and superficial tissues.
Why 660nm Dominates
Of all the visible red wavelengths, 660nm has the strongest evidence base and is used in the vast majority of consumer devices. There are specific reasons for this:
Cytochrome c oxidase absorption peak. Cytochrome c oxidase (CCO) — the enzyme in the mitochondrial electron transport chain that acts as the primary photoacceptor for PBM — has an absorption peak near 660nm in its oxidised state. When CCO absorbs photons at this wavelength, it releases nitric oxide from its binding site, allowing the enzyme to function more efficiently and increasing ATP production (Karu, 2010; PMID: 20662021).
Optimal penetration for dermal targets. At 660nm, light penetrates 3-5mm into tissue — deep enough to reach the dermis (where collagen is produced) and the hair follicle bulge region, but not so deep that energy is wasted on non-target tissue.
Clinical evidence volume. 660nm has been used in more published clinical trials than any other single visible red wavelength. Studies on skin rejuvenation (Wunsch & Matuschka, 2014; PMID: 24286286), hair growth (Lanzafame et al., 2014; PMID: 24078483), wound healing, and inflammatory skin conditions consistently use this wavelength.
The Other Red Wavelengths
620-630nm wavelengths penetrate less deeply and are primarily useful for very superficial targets: the epidermis, superficial wounds, and surface-level skin conditions. Some LED masks use 630nm for general skin health and collagen stimulation. The evidence is solid, though 660nm tends to outperform in head-to-head comparisons for most conditions.
633nm is notable for its specific use in acne treatment, particularly in combination with blue light (415nm). The Omnilux system — one of the few LED devices with substantial clinical trial evidence — uses this wavelength. Lee et al. (2007; PMID: 17566756) demonstrated significant acne reduction with combined blue/red LED therapy.
670nm occupies a special position as the primary wavelength used in NASA’s LED research programme. Harry Whelan’s team at the Medical College of Wisconsin demonstrated accelerated wound healing at this wavelength (Whelan et al., 2001; PMID: 11706695). More recently, 670nm has attracted attention for retinal health — Glen Jeffery’s research at University College London showed that brief 670nm exposure improved declining colour contrast vision in participants over 40 (PMID: 32601258).
680-700nm wavelengths sit at the boundary between visible red and near-infrared. They penetrate slightly deeper than 660nm but have substantially less published research. Few commercial devices specifically target these wavelengths.
The Near-Infrared Window: 700-1100nm
Near-infrared (NIR) wavelengths are invisible to the human eye. They penetrate far deeper into tissue than visible red light, reaching muscle, bone, joints, and — through the skull — brain tissue. This makes NIR essential for any condition involving structures beneath the skin surface.
The Critical Wavelengths
810nm is arguably the most important NIR wavelength for photobiomodulation. It corresponds to a second absorption peak of cytochrome c oxidase (in its reduced state) and has the deepest evidence base of any NIR wavelength. Key applications include:
- Transcranial PBM (brain health). 810nm penetrates the skull sufficiently to reach cortical brain tissue. Naeser et al. (2014; PMID: 25587907) demonstrated cognitive improvement in chronic traumatic brain injury patients using 810nm LEDs. Subsequent research has explored applications in Alzheimer’s disease, depression, and cognitive enhancement.
- Deep tissue repair. Muscle injuries, tendon damage, and ligament healing all show positive responses at 810nm.
- Pain management. Chronic and acute pain conditions respond well to 810nm, particularly when the pain source is deep (e.g., joint capsule, deep muscle).
830nm penetrates slightly deeper than 810nm and has excellent evidence for musculoskeletal conditions. Bjordal et al. (2003; PMID: 12580887) included 830nm in their systematic review showing significant pain reduction in joint disorders. This wavelength is commonly used in professional physiotherapy devices.
850nm is the “workhorse” NIR wavelength in consumer devices, much as 660nm is for visible red. It offers deep penetration (20-30mm), strong evidence across multiple conditions, and is readily available in high-power LED configurations. Ferraresi et al. (2012; PMID: 22988275) demonstrated enhanced muscle recovery and reduced markers of exercise-induced damage using 850nm.
880nm was one of the two primary wavelengths in NASA’s research programme (alongside 670nm). It is less commonly used in modern consumer devices than 850nm, largely because 850nm LEDs are more widely manufactured and have comparable biological effects.
904nm is primarily used in pulsed laser therapy devices rather than LED panels. The superpulsed 904nm laser is a staple of professional physiotherapy, with strong evidence for pain management, particularly in joint conditions and tendinopathies.
940nm and Beyond
940nm has attracted attention for its ability to penetrate adipose (fat) tissue more effectively than shorter NIR wavelengths. Some devices targeting fat reduction or body contouring use this wavelength. The evidence is growing but not yet as robust as for 810-850nm.
980nm sits at a water absorption peak, meaning much of its energy is absorbed by tissue water and converted to heat rather than driving photochemical reactions. This makes it useful in some surgical laser applications (tissue cutting, coagulation) but less suitable for photobiomodulation.
1060nm has limited but emerging evidence for deep tissue applications. Some multi-wavelength devices include it to target bone tissue and deeper fat layers. The evidence base is thin compared to the 810-850nm range.
Beyond 1100nm, water absorption increases dramatically, reducing penetration depth and shifting the interaction from photochemical to purely photothermal. This is outside the therapeutic window for photobiomodulation.
The “Dead Zone”: 700-770nm
If you examine the master wavelength table, you will notice a conspicuous gap between approximately 700nm and 770nm. Very few therapeutic devices use wavelengths in this range, and for good reason.
Poor chromophore absorption. Cytochrome c oxidase — the primary target of photobiomodulation — has absorption peaks near 660nm (oxidised form) and 810nm (reduced form). The 700-770nm range falls between these peaks, in a trough of CCO absorption. Photons at these wavelengths are less efficiently absorbed by the target enzyme.
Competing absorbers. In this range, other tissue chromophores (particularly water and deoxyhemoglobin) begin to absorb more strongly, competing with CCO for photon energy and reducing the proportion of light that drives beneficial photochemical reactions.
Minimal research. Because the biophysical rationale is weak, very few researchers have studied this range. There are almost no clinical trials using wavelengths between 700nm and 770nm for photobiomodulation. Absence of evidence is not evidence of absence, but there is currently no reason to prefer these wavelengths over better-studied alternatives.
The practical consequence: if a device uses wavelengths in this range, be sceptical. It may indicate that the manufacturer selected LEDs based on cost and availability rather than therapeutic evidence.
Multi-Wavelength vs Single-Wavelength Devices
Modern red light therapy devices range from single-wavelength panels to devices offering five or more wavelengths simultaneously. Understanding the trade-offs is important.
Two-Wavelength Devices (660nm + 850nm)
The most common configuration in consumer panels. This combination provides:
- Full coverage of both CCO absorption peaks
- Superficial treatment (skin, hair) via 660nm
- Deep tissue treatment (muscle, joints, bone) via 850nm
- The broadest evidence base of any wavelength combination
For most users, a quality 660nm + 850nm device covers the vast majority of evidence-backed applications. This is the recommended starting point for general use.
Three-Wavelength Devices (e.g., 630nm + 660nm + 850nm)
Adding a third wavelength — typically a shorter red like 630nm — provides slightly broader superficial coverage. The marginal benefit over a two-wavelength device is small for most applications, but some users treating purely superficial skin conditions may benefit from the additional red wavelength.
Five-Wavelength Devices (e.g., 630nm + 660nm + 810nm + 830nm + 850nm)
Several premium devices (notably the BioMax series from PlatinumLED) offer five wavelengths spanning both visible red and NIR ranges. The rationale is:
- Multiple CCO absorption peaks are targeted simultaneously
- Broader penetration range — from 1mm (630nm) to 30mm+ (850nm)
- Condition versatility — a single device can address skin, muscle, joint, brain, and bone targets
The trade-off is cost and complexity. Each additional wavelength adds manufacturing cost. And because the total output power of a device is divided among its wavelengths, a five-wavelength panel at a given wattage delivers less power per wavelength than a two-wavelength panel at the same wattage.
How to Decide
| Your primary goal | Recommended wavelengths | Why |
|---|---|---|
| Skin rejuvenation / anti-ageing | 630nm + 660nm | Both in the CCO absorption range for dermal targets |
| Acne | 633nm (+ 415nm blue if available) | Best clinical evidence for this combination |
| Hair growth | 650nm or 660nm | Both studied in hair growth trials |
| Muscle recovery / sports | 850nm (or 810nm + 850nm) | Deep penetration to muscle tissue |
| Joint pain / arthritis | 830nm or 850nm | Penetrates to joint capsule depth |
| Brain health / TBI / cognition | 810nm | Best-studied wavelength for transcranial PBM |
| General wellness (all-purpose) | 660nm + 850nm | Covers both peaks; broadest evidence |
| Deep tissue + superficial skin | 630nm + 660nm + 810nm + 850nm | Full-spectrum approach |
Common Wavelength Combinations in Popular Devices
| Device | Wavelengths | Configuration |
|---|---|---|
| Joovv Solo 3.0 | 660nm + 850nm | Dual-wavelength, switchable or combined |
| PlatinumLED BioMax 600 | 630nm + 660nm + 810nm + 830nm + 850nm | Five wavelengths, simultaneous |
| Mito Red MitoPRO 1500 | 630nm + 660nm + 830nm + 850nm | Four wavelengths |
| Rouge Ultimate | 660nm + 850nm | Dual-wavelength |
| Bestqool Pro300 | 660nm + 850nm | Dual-wavelength, budget option |
| Celluma Pro | 465nm + 640nm + 880nm | Three wavelengths (includes blue) |
| Omnilux Contour | 633nm + 830nm | Medical-grade, FDA-cleared |
| Kineon Move+ Pro | 808nm (laser) + 650nm (LED) | Laser/LED hybrid for joints |
| Flexbeam | 630nm + 660nm + 850nm | Three-wavelength, portable |
| Hooga HG1500 | 660nm + 850nm | Dual-wavelength, value |
Why Some Devices Use 5 Wavelengths vs 2
The five-wavelength approach is driven by a plausible — though not yet conclusively proven — hypothesis: that targeting multiple absorption peaks simultaneously produces a synergistic effect greater than the sum of individual wavelengths.
The argument for multi-wavelength:
- Broader absorption coverage. CCO has multiple absorption bands. Hitting several simultaneously may activate a larger proportion of the enzyme population.
- Depth stratification. Different wavelengths penetrate to different depths. A five-wavelength device treats from epidermis (630nm) to deep bone (850nm) simultaneously.
- Diverse chromophore targeting. Beyond CCO, other cellular chromophores (opsins, flavins, porphyrins) respond to different wavelengths. Multi-wavelength exposure may trigger multiple beneficial pathways.
The argument for simplicity (two wavelengths):
- Evidence concentration. The overwhelming majority of positive clinical trials used single-wavelength or dual-wavelength protocols. There are very few trials directly comparing multi-wavelength to dual-wavelength outcomes.
- Power distribution. A 300W panel with five wavelengths delivers roughly 60W per wavelength. The same panel with two wavelengths delivers 150W per wavelength — 2.5 times the power density at each therapeutic wavelength.
- Cost. Multi-wavelength devices cost more. If the clinical benefit is marginal, the additional investment may not be justified.
The honest answer: for most people, 660nm + 850nm is sufficient and well-supported by evidence. Multi-wavelength devices are a reasonable choice if budget allows, but the incremental benefit over a quality dual-wavelength panel has not been conclusively demonstrated in clinical research.
Matching Wavelengths to Your Condition
When choosing a device, start with the condition you want to treat and work backwards to the wavelength:
| Condition Category | Target Tissue | Depth Required | Best Wavelengths |
|---|---|---|---|
| Surface skin (acne, redness, fine lines, texture) | Epidermis, upper dermis | 1-3mm | 630nm, 633nm, 660nm |
| Deep skin (collagen, scarring, pigmentation) | Dermis, dermal-epidermal junction | 3-5mm | 660nm, 670nm |
| Hair growth | Hair follicle bulge, dermal papilla | 3-5mm | 650nm, 660nm |
| Superficial wounds | Epidermis, dermis | 1-5mm | 630nm, 660nm, 670nm |
| Muscle recovery | Skeletal muscle | 10-30mm | 810nm, 850nm |
| Tendons / ligaments | Connective tissue | 5-20mm | 810nm, 830nm |
| Joint pain / arthritis | Synovium, cartilage, capsule | 15-30mm | 830nm, 850nm |
| Bone healing / density | Cortical and trabecular bone | 20-40mm | 830nm, 850nm, 904nm (pulsed) |
| Brain / cognitive | Cerebral cortex | 20-30mm (through skull) | 810nm |
| Nerve pain / neuropathy | Peripheral nerves | 5-20mm | 810nm, 830nm |
| Fat reduction | Subcutaneous adipose | 10-25mm | 635nm, 940nm, 1060nm |
Key Takeaways
- 660nm and 850nm are the two most important wavelengths in red light therapy, covering both peaks of cytochrome c oxidase absorption and the full range from superficial to deep tissue
- The 700-770nm “dead zone” falls between CCO absorption peaks — avoid devices that rely heavily on these wavelengths
- Multi-wavelength devices offer theoretical advantages but limited proof of superiority over well-made dual-wavelength panels
- Always match wavelength to your condition — surface skin issues need red (620-670nm), deep tissue needs NIR (810-850nm)
- More wavelengths does not automatically mean better — power density per wavelength matters as much as wavelength count
References
- Avci P, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg. 2013;32(1):41-52. PMID: 23508258
- Wunsch A, Matuschka K. A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase. Photomed Laser Surg. 2014;32(2):93-100. PMID: 24286286
- Lee SY, et al. A prospective, randomized, placebo-controlled, double-blinded, and split-face clinical study on LED phototherapy for skin rejuvenation. J Photochem Photobiol B. 2007;88(1):51-67. PMID: 17566756
- Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. PMID: 28748217
- Whelan HT, et al. Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg. 2001;19(6):305-314. PMID: 11706695
- Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life. 2010;62(8):607-610. PMID: 20662021
- Lanzafame RJ, et al. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med. 2013;45(8):487-495. PMID: 24078483
- Naeser MA, et al. Significant improvements in cognitive performance post-transcranial, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury. Arch Clin Neuropsychol. 2014;29(8):783-796. PMID: 25587907
- Bjordal JM, et al. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Aust J Physiother. 2003;49(2):107-116. PMID: 12580887
- Ferraresi C, et al. Low-level laser (light) therapy (LLLT) on muscle tissue: performance, fatigue and repair benefited by the power of light. Photonics Lasers Med. 2012;1(4):267-286. PMID: 22988275
- Shackley DC, et al. Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours. BJU Int. 2000;86(6):638-643. PMID: 11069370
- Huang YY, et al. Biphasic dose response in low level light therapy. Dose Response. 2009;7(4):358-383. PMID: 20011653
Related topics: red light therapy wavelength chart · red light therapy nm chart · red light therapy spectrum
Find the right device
Compare 20+ red light therapy devices by wavelength, irradiance, and value.